Clinical trials: Hyperlipoproteinemia
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Hyperlipidemia
Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation
The purpose of this 8-week intervention trial is to investigate the effect of a dietary supplement (containing citrus bioflavonoids and vitamin E) plus fish oil supplementation in healthy hyperlipidemic subjects
- Trial name
- NCT01671254
- Testing
- FishOil, CBE75, CBE150
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- MetaProteomics LLC
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol
To evaluate the efficacy, safety, pharmacodynamics and immunogenicity of QLC7401 subcutaneous administration in patients with primary hypercholesterolemia or mixed hyperlipidemia with poorly controlled LDL-C elevated on optimized…
- Trial name
- NCT06750341
- Testing
- QLC7401
- Volunteers
- 156 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hypertension, Hyperlipidemia
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
The purpose of the study is to measure the effect of the amlodipine/atorvastatin combination pill in reducing both elevated blood pressure and cholesterol levels to levels suggested by guidelines
- Trial name
- GEMINI-AALA (NCT00143234)
- Testing
- Amlodipine/atorvastatin single pill
- Where
- 118 sites in Argentina, Australia and 25 more
- Volunteers
- 1,825 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hyperlipoproteinemia Type II, Homozygous Familial Hypercholesterolemia
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
This study will evaluate the safety and effect of anacetrapib on low-density lipoprotein-cholesterol (LDL-C) when added to ongoing lipid-lowering therapy.
- Trial name
- NCT01841684
- Testing
- Anacetrapib
- Volunteers
- 2 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia, Hypertension
To Evaluate the Safety and PK Characteristics in Healthy Volunteers-Livalozet
The purpose of this study is to compare pharmacokinetics between Pitavastatin and Valsartan co-administration and Livalo fixed combination drug in healthy male subjects.
- Trial name
- NCT01764178
- Testing
- Livalo fixed combination drug, Pitavastatin, Valsartan
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Hyperlipidemia
Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal
This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the…
- Trial name
- CRE NIS (NCT00781560)
- Where
- 15 sites in China
- Volunteers
- 2,575 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Familial
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy
The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 (mipomersen) as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia
- Trial name
- NCT00281008
- Where
- 8 sites in United States, Netherlands
- Volunteers
- 44 people
- Sponsor
- Kastle Therapeutics, LLC
Homozygous Familial Hypercholesterolemia
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) with alirocumab subcutaneous (SC) every 2 weeks (Q2W) in comparison to placebo after 12 weeks of treatment.
- Trial name
- ODYSSEY HoFH (NCT03156621)
- Testing
- Alirocumab
- Where
- 28 sites in United States, Austria and 11 more
- Volunteers
- 69 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension,, Hyperlipidemia
Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia
This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and…
- Trial name
- NCT01918332
- Testing
- Valsartan 160mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 168 people
- Sponsor
- LG Life Sciences
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy.
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- RADICHOL 1 (NCT00607373)
- Testing
- mipomersen
- Where
- 10 sites in United States, Brazil and 5 more
- Volunteers
- 51 people
- Sponsor
- Kastle Therapeutics, LLC
Familial Hypercholesterolemia
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.
- Trial name
- HAUSER-OLE (NCT02624869)
- Testing
- Evolocumab
- Where
- 46 sites in United States, Australia and 21 more
- Volunteers
- 163 people
- Sponsor
- Amgen
Hyperlipidemia
A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and…
- Trial name
- NCT07230730
- Testing
- SHR-1918
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Hypercholesterolemia, Familial Hypercholesterolemia
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
The goal of this study is to evaluate the efficacy, safety, and tolerability of enlicitide decanoate in adult participants with heterozygous familial hypercholesterolemia.
- Trial name
- NCT05952869
- Testing
- Enlicitide Decanoate
- Where
- 59 sites in United States, Australia and 15 more
- Volunteers
- 303 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia
Impact of a Chewable Plant Sterol Supplement on LDL-C in A Real-World Setting
The purpose of this study is to measure the effectiveness of a twice daily plant sterol supplement, which is in a gummy format and packaged with health insights, in reducing LDL-C cholesterol in a real word setting.
- Trial name
- NCT04642742
- Testing
- Chewable plant sterol
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Piper Biosciences, Inc.
Hyperlipidemia
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)
To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.
- Trial name
- NCT00211705
- Testing
- Diet, Diet+pravastatin
- Volunteers
- 8,000 people
- Sponsor
- Mitsukoshi Health and Welfare Foundation
Primary Hypercholesterolaemia, Mixed Hyperlipidaemia
Lipid Efficacy/Tolerability Study (0524A-020)
A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups.
- Trial name
- NCT00269204
- Testing
- niacin (+) laropiprant, ER-niacin
- Volunteers
- 1,620 people
- Sponsor
- Merck Sharp & Dohme LLC
Hyperlipidemia, Dyslipidemia
A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of combination cholesterol medications to…
- Trial name
- NCT00267267
- Testing
- torcetrapib/atorvastatin, ezetimibe/simvastatin
- Where
- 123 sites in United States
- Volunteers
- 1,784 people
- Sponsor
- Pfizer
Hypertension, Hyperlipidemia
Bioequivalence Study of CJ-30061 in Healthy Male Volunteers
To compare the pharmacokinetics and safety after a single dose administration of CJ-30061 and co-administration of Exforge® 5/160mg, Lipitor® 20mg in healthy adult volunteers
- Trial name
- NCT03657472
- Testing
- CJ-30061, Exforge® 5/160mg & Lipitor® 20mg
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Coronary Heart Disease, Hypercholesterolemia
Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)
This observational study is being conducted in patients receiving statin treatment as secondary prevention of coronary heart disease under the current standard of care in compliance with European guidelines.
- Conditions
- Coronary Heart Disease, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT00723723
- Testing
- Statin
- Volunteers
- 555 people
- Sponsor
- Organon and Co